NurExone Biologic Inc.
NRX.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -109.77% | -8.04% | -27.40% | -30.78% | 27.32% |
| Total Depreciation and Amortization | 1,200.00% | 0.00% | 116.67% | 150.00% | 200.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 66.50% | 184.68% | -14.89% | 192.31% | 655.56% |
| Change in Net Operating Assets | -466.67% | -59.00% | 421.05% | -493.88% | -138.08% |
| Cash from Operations | -174.09% | -3.68% | -25.00% | -78.01% | 19.77% |
| Capital Expenditure | 31.34% | -30,200.00% | -2,950.00% | -363.46% | -1,216.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -95.65% | -- | -- | -- | -- |
| Cash from Investing | -2.27% | -30,200.00% | -3,450.00% | -363.46% | -833.33% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 12.50% | 27.27% | -600.00% | 0.00% | -- |
| Issuance of Common Stock | 345.12% | 19.00% | -- | -- | 496.36% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -454.78% | 20.00% | -- | -- | -634.88% |
| Cash from Financing | 96.67% | 19.79% | 4,500.00% | 55,075.00% | -8.16% |
| Foreign Exchange rate Adjustments | -1,366.67% | -- | 400.00% | 175.00% | -400.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -202.82% | -47.53% | -22.88% | 410.17% | 12.50% |